Search research articles
Contact Us
Filters
Showing results (71-80 of 93) with videos related to
Page
of 10
Sort By:
Journal of Clinical Gastroenterology
|
March 11, 2010
Hepatocellular carcinoma (HCC): a global perspective
Peter Ferenci, Michael Fried, Douglas Labrecque, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|
March 29, 2017
ANGPTL8 (Betatrophin) is Expressed in Visceral Adipose Tissue and Relates to Human Hepatic Steatosis in Two Independent Clinical Collectives
Christian von Loeffelholz, Andreas F H Pfeiffer, Johan F Lock, et al.
The Lancet. Gastroenterology & Hepatology
|
December 6, 2016
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
George Lau, Yves Benhamou, Guofeng Chen, et al.
Future Oncology (London, England)
|
May 11, 2026
Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)
Lorenza Rimassa, Stephen L Chan, Bruno Sangro, et al.
Hepatology International
|
July 1, 2026
APASL clinical practice guidance: the diagnosis and management of patients with Wilson's disease
Wei Zhang, Hong You, Xiaojuan Ou, et al.
Journal of Hepatology
|
August 1, 2024
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
George Lau, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
Journal of Hepatology
|
April 13, 2025
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
Lorenza Rimassa, Stephen L Chan, Bruno Sangro, et al.
Scientific Reports
|
March 9, 2024
Ammonia is associated with liver-related complications and predicts mortality in acute-on-chronic liver failure patients
Kessarin Thanapirom, Sombat Treeprasertsuk, Ashok Choudhury, et al.
Hepatology International
|
January 25, 2022
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
George Lau, Ming-Lung Yu, Grace Wong, et al.
Future Oncology (London, England)
|
September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 93) with videos related to
Sort By:
Page
of 10
Journal of Clinical Gastroenterology
|
March 11, 2010
Hepatocellular carcinoma (HCC): a global perspective
Peter Ferenci, Michael Fried, Douglas Labrecque, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|
March 29, 2017
ANGPTL8 (Betatrophin) is Expressed in Visceral Adipose Tissue and Relates to Human Hepatic Steatosis in Two Independent Clinical Collectives
Christian von Loeffelholz, Andreas F H Pfeiffer, Johan F Lock, et al.
The Lancet. Gastroenterology & Hepatology
|
December 6, 2016
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
George Lau, Yves Benhamou, Guofeng Chen, et al.
Future Oncology (London, England)
|
May 11, 2026
Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer)
Lorenza Rimassa, Stephen L Chan, Bruno Sangro, et al.
Hepatology International
|
July 1, 2026
APASL clinical practice guidance: the diagnosis and management of patients with Wilson's disease
Wei Zhang, Hong You, Xiaojuan Ou, et al.
Journal of Hepatology
|
August 1, 2024
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
George Lau, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
Journal of Hepatology
|
April 13, 2025
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC
Lorenza Rimassa, Stephen L Chan, Bruno Sangro, et al.
Scientific Reports
|
March 9, 2024
Ammonia is associated with liver-related complications and predicts mortality in acute-on-chronic liver failure patients
Kessarin Thanapirom, Sombat Treeprasertsuk, Ashok Choudhury, et al.
Hepatology International
|
January 25, 2022
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy
George Lau, Ming-Lung Yu, Grace Wong, et al.
Future Oncology (London, England)
|
September 6, 2023
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
Ghassan K Abou-Alfa, George Lau, Masatoshi Kudo, et al.
Page
of 10